 |
Список литературы
|
|
|
|
1. Leask A, Abraham DJ. TGF‐ beta signaling and the fibrotic response. FASEB J. 2004; 18: 816–827.
2. Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black С. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum. 1994; 37: 278– 288.
3. Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K. Demonstration of interleukin‐ 2, interleukin‐ 4 and interleukin‐ 6 in sera from patients with localized scleroderma. Arch Dermatol Res. 1995; 287: 193– 197.
4. Kreuter A, Hyun J, Skrygan M et al. Ultraviolet al‐ induced downregulation of human beta‐ defensins and interleukin‐ 6 and interleukin‐ 8 correlate with clinical improvement in localized scleroderma. Br J Dermatol. 2006; 155: 600– 607.
5. Yamamoto T. Chemokines and chemokine receptors in scleroderma. Int Arch Allergy Immunol. 2006; 140: 345– 356.
6. Gambichler T, Skrygan M, Labanski AA, Kolios AG, Altmeyer P, Kreuter A. Significantly increased CCL5/RANTES and CCR7 mRNA levels in localized scleroderma. Regul Pept. 2011; 170: 4– 6.
7. Fett N, Werth VP. Update on morphea. Part I. Epidemiology, clinical presentation, and pathogenesis. Journal of the American Academy of Dermatology. 2011; 64(2): 217‐ 28.
8. Saxton‐ Daniels S, Jacobe HT. An evaluation of long‐ term outcomes in adults with pediatric‐ onset morphea. Archives of Dermatology. 2010; 146(9): 1044‐ 5.
9. Asano Y, Fujimoto M, Ishikawa O, Sato S, Jinnin M, Takehara K, et al. Diagnostic criteria, severity classification and guidelines of localized scleroderma. Journal of Dermatology. 2018; 45(7): 755‐ 80.
10. Ресурсы и деятельность медицинских организаций дерматовенерологического профиля. Заболеваемость инфекциями, передаваемыми половым путем, заразными кожными болезнями и заболеваниями кожи за 2017-2018 годы (статистические материалы). Москва 2019. Стр. 208.
11. Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006; 18(6): 606–613.
12. Orozco-Covarrubias L, Guzman-Meza A, Ridaura-Sanz C, Carrasco Daza D, Sosa-de-Martinez C, Ruiz-Maldonado R. Scleroderma ‘en coup de sabre’ and progressive facial hemiatrophy. Is it possible to differentiate them? J Eur Acad Dermatol Venereol. 2002; 16: 361–366.
13. Kister I, Inglese M, Laxer RM, Herbert J. Neurologic manifestations of localized scleroderma: a case report and literature review. Neurology. 2008, 4; 71(19).
14. Florez-Pollack S, Kunzler E, Jacobe HT. Morphea: Current concepts. Clinics in Dermatology. 2018; 36: 475–486.
|
|
|
15. Gorkiewicz-Petkow A., Kalinska-Bienias A. Systemic involvement in localized scleroderma/morphea. Clinics in Dermatology. 2015; 33: 556–562.
16 Zulian. F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira S, Punaro M G, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford). 45 (2006): 614-620.
17. Tollefson M M, Witman P M. En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients. J Am Acad Dermatol. 2007; 56: 257-263.
18. Weibel L, Laguda B, Atherton D, Harper J I. Misdiagnosis and delay in referral of children with localized scleroderma. Br J Dermatol. 2011; 165: 1308-1313.
19. Piram M,. McCuaig C C, Saint-Cyr C, Marcoux D, Hatami A, Haddad, et al. Short- and long-term outcome of linear morphea in children. Br J Dermatol. 2013; 169: 1265-1271
20. Blaszczyk M, Krolicki L, Krasu M, Glinska O, Jablonska S. Progressive facial hemiatrophy: central nervous system involvement and relationship with scleroderma en coup de sabre. J Rheumatol. 2003; 30: 1997-2004.
21. Christen-Zaech S, Hakim M. D, Afsar F. S, Paller A. S. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol. 2008; 59: 385-396.
22. Jorre S. Mertens, Marieke M. B. Seyger, Rogier M. Thurlings, Timothy R. D. J. Radstake, Elke M. G. J. de Jong. Morphea and Eosinophilic Fasciitis: An UpdateAm J Clin Dermatol. 2017; 18(4): 491–512.
23. George R, George A, and Kumar TS. Update on Management of Morphea (Localized Scleroderma) in Children. Indian Dermatol Online J. 2020 Mar-Apr; 11(2): 135–145.
24. Arkachaisri T, Fertig N, Pino S, Medsger TA Jr. Serum autoantibodies and their clinical associations in patients with childhood- and adultonset linear scleroderma. A single-center study. J Rheumatol. 2008; 35: 2439–2444.
25. Knobler R, Moinzadeh P, Hunzelmann N, et al. European Dermatology. Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatol Venereol. 2017; 31: 1401-1424.
26. Sato S, Fujimoto M, Kikuchi K, et al. Soluble CD4 and CD8 in serum from patients with localized scleroderma. Arch Dermatol Res. 1996; 288: 358-362.
27. Clements PJ. Penicillamine in the treatment of systemic sclerosis. Curr Rheumatol Rep. 1999 Oct; 1(1): 38-42.
28. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008; 58: 3902–12.
29. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35: 35–42.
30. Krieg T, Takehara K. Skin disease: a cardinal feature of systemic sclerosis. Rheumatology (Oxford). 2009; 48(3): 14-18.
31. Desbois A C, Cacoub P. Systemic sclerosis: An update in 2016. Autoimmun Rev. 2016 May; 15(5): 417-26.
32. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013; 65(11): 2737-2747.
|
|
|
33. Aberer E, Klade H, Stanek G, Gebhart W. Borrelia burgdorferi and different types of morphea. Dermatologica. 1991; 182(3): 145-54.
34. Sommer A, Gambichler T, Bacharach-Buhles M, von Rothenburg T, Altmeyer P, Kreuter A. Clinical and serological characteristics of progressive facial hemiatrophy: a case series of 12 patients. J Am Acad Dermatol 2006; 54: 227–233.
35. Tollefson M M, Witman P M. En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients. J Am Acad Dermatol. 2007; (56): 257-263
36. Fett N, Werth VP. Update on morphea: part II. Outcome measures and treatment. J Am Acad Dermatol. 2011; 64: 231-242.
37. Horger M, Fierlbeck G, Kuemmerle-Deschner J, Tzaribachev N, Wehrmann M, Claussen CD, et al. MRI findings in deep and generalized morphea. Am J Roentgenol 2008; 190: 32-9.
38. Schanz S, Fierlbeck G, Ulmer A, Schmalzing M, Kü mmerle-Deschner J, Claussen CD, et al. Localized scleroderma: MR findings and clinical features. Radiology 2011; 260: 817-24.
39. Florez-Pollack S, Kunzler E, Jacobe HT. Morphea: Current concepts. Clinics in Dermatology. 2018; 36: 475–486.
40. Onajin O, Wieland CN, Peters MS, et al. Clinicopathologic and immunophenotypic features of eosinophilic fasciitis and morphea profunda: a comparative study of 27 cases. J Am Acad Dermatol. 2018; 78: 121-128.
41. Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol. 2008; 59: 385–396.
42. Mertens JS, Seyger М M B, Thurlings R M, Radstake T R, de Jong E M. Morphea and Eosinophilic Fasciitis: An Update. Am J Clin Dermatol. 2017; 18(4): 491–512.
43. Walters R, Pulitzer M, Kamino H. Elastic fiber pattern in scleroderma/morphea. J Cutan Pathol. 2009; 36: 952–7.
44. Zannin ME, Martini G, Athreya BH, et al. Ocular involvement in children with localised scleroderma: a multi-centre study. Br J Ophthalmol. 2007; 91: 1311-4.
45. George R, George A, Kuma T. Update on Management of Morphea (Localized Scleroderma) in Children/ Indian Dermatol Online J. 2020; 11(2): 135–145.
46. Strickland N, Patel G, Strickland A, Jacobe H. Attitudes and trends in the treatment of morphea: a national survey. J Am Acad Dermatol. 2015; 72(4): 727–728.
47. Kreuter A, Krieg T, Worm M, Wenzel J, Moinzadeh P, Kuhn A, Aberer E, Scharffetter-Kochanek K, Horneff G, Reil E, Weberschock T, Hunzelmann N German guidelines for the diagnosis and therapy of localized scleroderma. J Dtsch Dermatol Ges. 2016 Feb; 14(2): 199-216.
48. Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol. 2002; 138 (1): 99–105.
49. Kroft E. B, Groeneveld TJ, Seyger МM, de Jong EM. Efficacy of topical tacrolimus 0. 1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol 2009; 10 (3): 181–187.
50. Stefanaki C, Stefanaki K, Kontochristopoulos G, Antoniou C, Stratigos A, Nicolaidou E, Gregoriou S, Katsambas A. Topical tacrolimus 0. 1% ointment in the treatment of localized scleroderma. An open label clinical and histological study. J Dermatol. 2008; Nov; 35(11): 712-8.
51. Хамаганова И. В., Чулкова Е. В., Акулова С. Е. Применение актовегина в дерматологической практике. Вестн дерматол венерол. 1995; 5: 47–49.
52. Kreuter A, Hyun J, Stü cker M. et al. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol. 2006; 54 (3): 440–447.
53. Kroft EB, Berkhof NJ, van de Kerkhof PC. et al. Ultraviolet A phototherapy for sclerotic skin diseases: a systematic review. J Am Acad Dermatol. 2008; 59 (6): 1017–1030.
54. Wang F, Garza LA, Cho S et al. Effect of increased pigmentation on the antifibrotic response of human skin to UV‐ A1 phototherapy. Arch Dermatol. 2008; 144: 851– 8.
|
|
|
55. Tuchinda C, Kerr HA, Taylor CR. et al. UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States. Photodermatol Photoimmunol Photomed. 2006; 22(5): 247—253.
56. Aljasser MI, Lui H, Ball NJ, Kalia S. Persistent polymorphous light eruption after ultraviolet A1 phototherapy. Photodermatol Photoimmunol Photomed. 2013; 29(1): 52—54.
57. Физическая и реабилитационная медицина. Национальное руководство. Под редакцией Г. Н. Пономаренко. Москва. 2016г. С. 660.
58. Частная физиотерапия. Под редакцией Г. Н. Пономаренко. Москва. 2005г. С. 726.
59. Breuckmann F, Gambichler T, Altmeyer P, Kreuter A. UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review. BMC Dermatol. 2004; 20; 4(1): 11.
60. Brenner M, Herzinger T, Berking C. et al. Phototherapy and photochemotherapy of sclerosing skin diseases. Photodermatol Photoimmunol Photomed. 2005; 21: 157–165.
61. Волнухин В. А., Мурадян Н. Л., Выборнова О. В., Боровая О. В. Фотохимиотерапия склеродермии и склеродермоподобных заболеваний кожи. Вестн дерматол венерол. 2008; 4: 39–48.
62. Zwischenberger BA, Jacobe HT. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol. 2011; 65 (5): 925–941.
63. Лечение больных псориазом методом ПУВА-ванн. Медицинская технология № ФС-2006/251 от 15 августа 2006 года. Вестник дерматологии и венерологии, 2008; 3: 21-24.
64. Pavlotsky F, Sakka N, Lozinski A, Barzilai A. Bath psoralen-UVA photochemotherapy for localized scleroderma: experience from a single institute. Photodermatol Photoimmunol Photomed. 2013. 29(5): 247-52.
65. Morison W, Marwaha S, Beck L. PUVA-induced phototoxicity: incidence and causes. J Am Acad Dermatol. 1997; 36: 183—185.
65. Tanew A, Ortel B, Rappersberger K, Hö nigsmann H. 5-methoxypsoralen (Bergapten) for photochemotherapy. J Am Acad Dermatol. 1988; 18: 333—338.
67. Жилова М. Б., Бутарева М. М., Волнухин В. А.. Современные аспекты фототерапии псориаза. Вестник дерматологии и венерологии. 2010; 3: 27–32.
68. Seyger MM, van den Hoogen FH, de Boo T, de Jong EM. Low-dose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol. 1998; 39 (2 Pt 1): 220–225.
69. Kroft EB, Creemers MC, van den Hoogen FH, Boezeman JB, de Jong EM. Effectiveness, side-effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study. Br J Dermatol. 2009; 160: 1075–82.
70. Fitch PG, Rettig P, Burnham JM, Finkel TH, Yan AC, Akin E, et al. Treatment of pediatric localized scleroderma with methotrexate. J Rheumatol. 2006; 33: 609–14.
71. Cox D, O’Regan G, Collins S, Byrne A, Irvine A, Watson R. Juvenile localised scleroderma: a retrospective review of response to systemic treatment. Ir J Med Sci. 2008; 177: 343–6.
72. Marrani E, Foeldvari I, Lopez JA, Cimaz R, Simonini G. Comparing ultraviolet light A photo(chemo)therapy with Methotrexate protocol in childhood localized scleroderma: Evidence from systematic review and meta-analysis approach. Semin Arthritis Rheum. 2018 Dec; 48(3): 495-503.
|
|
|
73. Uziel Y, Feldman BM, Krafchik BR, et al. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr. 2000; 136: 91–5.
74. Weibel L, Sampaio MC, Visentin MT, et al. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br J Dermatol. 2006; 155: 1013–20.
75. Zulian F, Martini G, Vallongo C, et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2011; 63: 1998–2006.
76. Zulian F, Vallongo C, Patrizi A, et al. A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea). J Am Acad Dermatol. 2012; 67: 1151–6.
77. Torok KS, Arkachaisri T. Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study. J Rheumatol. 2012; 39: 286–94.
78. Kreuter A, Gambichler T, Breuckmann F, Rotterdam S, Freitag M, Stuecker M, Hoffmann K, Altmeyer P. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol. 2005 Jul; 141(7): 847-52.
79. Breathnach SM. Drug Reactions. In: Burns T, Breathnach S, Cox N, Griffiths C editor(s). Rook's Textbook of Dermatology. 8th Edition. Vol. 4, Wiley‐ Blackwell, 2010: 73. 1‐ 73. 177.
80. Mertens JS, van den Reek JM, Kievit W, van de Kerkhof PC, Thurlings RM, Radstake TR, Seyger MM, de Jong. Drug Survival and Predictors of Drug Survival for Methotrexate Treatment in a Retrospective Cohort of Adult Patients with Localized Scleroderma. Acta Derm Venereol. 2016; 96(7): 943-947.
81. Joly P, Bamberger N, Crickx B. et al. Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients. Arch Dermatol. 1994; 130 (5): 663–664.
82. Amy de la Bretè que M, Rybojad M, Cordoliani F. et al. Relapse of severe forms of adult morphea after oral corticosteroid treatment. J Eur Acad Dermatol Venereol. 2013; 27 (9): 1190–1191.
83. Falanga V, Medsger T A. Jr. D-penicillamine in the treatment of localized scleroderma. Arch Dermatol. 1990; 126: 5: 661–664.
84. Осминина М. К., Лыскина Г. А., Аммосова Е. П., Тугаринова Г. В., Рабиева Г. М. Д-пеницилламин в лечении ограниченных форм ювенильной склеродермии. Педиатрия 2008; 87: 4: 97-102.
85. Kaur S, Dhar S, Kanwar A J. Treatment of childhood linear morphea with D-penicillamine. Pediatr Dermatol. 1993; 10 (2): 201–202.
86. Brittany A, Zwischenberger, M, Heidi T. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol 2011; 65: 925-41.
87. Albuquerque J, Andriolo B, Vasconcellos M, et all. Interventions for morphea. Cochrane Database of Systematic Reviews Interventions for morphea (Review) Cochrane Database of Systematic Reviews. 2019; 7: 10-11.
88. Valanč ienė G, Jasaitienė D, Valiukevič ienė S. Pathogenesis and treatment modalities of localized scleroderma. Medicina (Kaunas). 2010; 46 (10): 649–656.
89. Дерматовенерология. Национальное руководство. Под редакцией проф. Ю. С. Бутова. Москва. 2013 г. С. 511.
90. Мордовцев В. Н., Скрипкин Ю. К. Справочник дерматолога. С-Петербург.: ГИППОКРАТ. 1999г. С. 254
91. Mö hrenschlager M, Jung C, Ring J, Abeck D. Effect of penicillin G on corium thickness in linear morphea of childhood: an analysis using ultrasound technique. Pediatric Dermatology. 1999; 16: 4: 314-316.
92. Kumar AB, Blixt EK, Drage LA, el-Azhary RA, Wetter DA. Treatment of Morphea With Hydroxychloroquine: A Retrospective Review of 84 Patients at Mayo Clinic, 1996-2013. J Am Acad Dermatol. 2019; 80: 1658-63.
93. Хмельницкий Р. Х. Опыт лечения склеродермии лидазой. Вестн дерматол венерол. 1958; 4: 66–68.
94. Рахманов В. А., Хмельницкий Р. Х. К механизму действия лидазы при лечении больных склеродермией. Вестн дерматол. 1959; 6: 3–7.
95. Данильянц Е. И. О лечении склеродермии лидазой. Мед. журн. Узбекистана. 1965; 5: 22–25.
96. Abbas LF, Coias BA, Jacobe BA, Heidi T, Nijhawan RI. Hyaluronidase injections for treatment of symptomatic pansclerotic morphea-induced microstomia. JAAD Case Rep. 2019; 25; 5(10): 871-873.
|
|
|
97. Melvin OG, Hunt BA, Jacobson S. Hyaluronidase Treatment of Scleroderma-Induced Microstomia. JAMA Dermatol. 2019; 155(7): 857-859.
98. De Souza RB, Macedo AR, Kuruma KA, Macedo PA, Borges CT. Pentoxyphylline in association with vitamin E reduces cutaneous fibrosis in systemic sclerosis. Clin Rheumatol. 2009; 28: 1207–12.
99. Neĭ koIe M, Iatsyshyn RI. Use of pentoxifylline in the treatment of systemic scleroderma. LikSprava. 2002; 1: 97–102.
100. Vishalakshi Viswanath, Meghana M Phiske, Vinay V Gopalani. Systemic Sclerosis: Current Concepts in Pathogenesis and Therapeutic Aspects of Dermatological Manifestations. Indian J Dermatol. 2013 Jul-Aug; 58(4): 255–268.
101. Goldman MP. The use of pentoxifylline in the treatment of systemic sclerosis and lipodermatosclerosis: a unifying hypothesis? J Am Acad Dermatol. 1994 Jul; 31(1): 135-6.
102. Berman B, Duncan MR. Pentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma and morphoea skin and their production of collagen, glycosaminoglycans and fibronectin. 1990. Sep; 123(3): 339-46.
103. Смирнов А. В., Главинская Т. А. Современные представления о патогенезе и возможностях терапии ограниченной склеродермии. Нижегородский медицинский журнал 1997; 3: 73–82.
104. Гребенюк В. Н. Ограниченная склеродермия у детей. Русский медицинский журнал 1998; 6 (6): 352–356.
105. Martini G, Ramanan AV, Falcini F et al. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology 2009; 48: 1410–3.
106. Mertens JS, Marsman D, Van de Kerkhof PCM, et al. Use of Mycophenolate Mofetil in Patients with Severe Localized Scleroderma Resistant or Intolerant to Methotrexate. Acta Derm. 2016; 96: 510–513.
107. Диденко И. Г. Терапевтическая эффективность ультразвука и фонофореза лидазы при различных формах склеродермии. Вестн дерматол венерол 1978; 6: 76–79.
108. Волнухин В. А., Харитонова Н. И., Знаменская Л. Ф. Опыт применения сочетанных методов низкоинтенсивной лазеротерапии при лечении заболеваний с проявлениями склероза и атрофии кожи. Лазерная медицина 1997; 1(2): 12-15.
109. Ананьева К. А., Вербенко Е. В. Новый метод лечения различных форм склеродермии электрофорезом с лидазой. Методики по диагностике, лечению и профилактике заболеваний, разработанные и усовершенствованные в МОНИКИ. М., 1970: 148–149.
110. Schoch JJ, Schoch BS, Werthel JD, McIntosh AL, Davis DM. Orthopedic complications of linear morphea: Implications for early interdisciplinary care. Pediatr Dermatol. 2018; 35: 43–6.
111. Buckley SL, Skinner S, James P, Ashley RK. Focal scleroderma in children: an orthopaedic perspective. J Pediatr Orthop. 1993; 13(6): 784-90.
112. Arkachaisri T, Vilaiyuk S, Li S, et al. The localized scleroderma skin severity Index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol. 2009; 36: 2819–29.
1. Приложение А1. Состав рабочей группы по разработке и пересмотру клинических рекомендаций
1. Кубанов Алексей Алексеевич – член-корреспондент РАН, доктор медицинских наук, профессор, президент Российского общества дерматовенерологов и косметологов. Конфликт интересов отсутствует.
2. Насонов Евгений Львович – академик РАН, доктор медицинских наук, профессор, президент Общероссийской общественной организации « Ассоциация ревматологов России». Конфликт интересов отсутствует.
3. Ананьева Лидия Петровна – доктор медицинских наук, член Общероссийской общественной организации « Ассоциация ревматологов России». Конфликт интересов отсутствует.
4. Алексеев Дмитрий Львович – кандидат медицинских наук, член Общероссийской общественной организации « Ассоциация ревматологов России». Конфликт интересов отсутствует.
5. Галлямова Юлия Альбертовна – доктор медицинских наук, член Российского общества дерматовенерологов и косметологов. Конфликт интересов отсутствует.
6. Гайдина Татьяна Анатольевна – кандидат медицинских наук, член Российского общества дерматовенерологов и косметологов. Конфликт интересов отсутствует.
7. Дворников Антон Сергеевич – доктор медицинских наук, член Российского общества дерматовенерологов и косметологов. Конфликт интересов отсутствует.
8. Жилова Марьяна Борисовна – доктор медицинских наук, член Российского общества дерматовенерологов и косметологов. Конфликт интересов отсутствует.
9. Знаменская Людмила Федоровна – доктор медицинских наук, член Российского общества дерматовенерологов и косметологов. Конфликт интересов отсутствует.
10. Никишина Ирина Петровна – кандидат медицинских наук, член Общероссийской общественной организации « Ассоциация ревматологов России». Конфликт интересов отсутствует.
11. Снарская Елена Сергеевна – доктор медицинских наук, член Российского общества дерматовенерологов и косметологов. Конфликт интересов отсутствует.
12. Текучева Лилиана Владимировна – кандидат медицинских наук, член Российского общества дерматовенерологов и косметологов. Конфликт интересов отсутствует.
|
|
|
